AstraZeneca reported third‑quarter 2025 results on Thursday, posting total revenue of $15.19 billion, up 12% year‑over‑year, and a reported earnings per share of $5.10, a 14% increase from the prior year. Core earnings per share rose to $7.04, reflecting a 15% year‑over‑year gain.
The company reaffirmed its full‑year 2025 outlook, targeting high‑single‑digit revenue growth and low‑double‑digit core EPS growth at constant exchange rates. Management highlighted that the guidance remains unchanged despite ongoing pricing pressures and the Medicare Part D redesign.
AstraZeneca’s performance was driven by strong sales in oncology, bioPharmaceuticals, and rare diseases, and the company announced 16 positive Phase III trials this year, including the pivotal data for baxdrostat, Enhertu, and Datroway. The robust pipeline and continued investment in U.S. manufacturing underpin the company’s confidence in sustaining growth.
With revenue and earnings beating consensus estimates, the results reinforce AstraZeneca’s competitive position and support its strategy to deliver an $80 billion revenue target by 2030. The company’s ability to maintain guidance amid regulatory and pricing headwinds signals resilience and a solid trajectory for the next fiscal year.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.